The compulsory licence dispute around Vertex’s high-priced cystic fibrosis drug Trikafta has again pushed South Africa’s long-delayed patent reform into the spotlight. Public-health groups and legal commentators argued on 8 July 2026 that, despite years of policy work, South Africa still relies on a depository-style patent system without full substantive examination, allowing weak pharmaceutical patents and evergreening risks to persist. At the same time, public materials from the Competition Commission and CIPC continue to indicate that the long-pending Patents Bill is meant to introduce substantive search and examination and modernise compulsory-licensing tools.
The immediate pressure is no longer just about one access-to-medicines dispute. It is about whether South Africa can finally connect stricter patentability standards, workable opposition routes and public-health safeguards in one legislative package. From a practical perspective, it would not be surprising if the DTIC now tries to move the Bill more quickly; the real impact for pharmaceutical and chemical businesses would be felt much earlier, at filing, prosecution and portfolio-planning stage, rather than only in later enforcement fights.
